<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Basilea Pharmaceutica Ag — News on 6ix</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag</link>
<description>Latest news and press releases for Basilea Pharmaceutica Ag on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 05:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/basilea-pharmaceutica-ag" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361a7f78dffbe2df13ecbd.webp</url>
<title>Basilea Pharmaceutica Ag</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag</link>
</image>
<item>
<title>Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-awarded-additional-carb-x-funding-of-usd-6-million-to-support-the-clinical-development-of-antibiotic-bal2420</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-awarded-additional-carb-x-funding-of-usd-6-million-to-support-the-clinical-development-of-antibiotic-bal2420</guid>
<pubDate>Thu, 09 Apr 2026 05:15:00 GMT</pubDate>
<description>Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical study Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced toda</description>
</item>
<item>
<title>Basilea announces start of first‑in‑human study of novel antibiotic BAL2420</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-start-of-firstinhuman-study-of-novel-antibiotic-bal2420</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-start-of-firstinhuman-study-of-novel-antibiotic-bal2420</guid>
<pubDate>Mon, 23 Mar 2026 06:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor. BAL2420 belongs to a novel class of antibiotics. I</description>
</item>
<item>
<title>Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-further-usd-6-million-from-barda-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-further-usd-6-million-from-barda-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam</guid>
<pubDate>Wed, 25 Feb 2026 06:15:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD</description>
</item>
<item>
<title>Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-reports-strong-2025-full-061500117</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-reports-strong-2025-full-061500117</guid>
<pubDate>Tue, 17 Feb 2026 06:15:00 GMT</pubDate>
<description>15% royalty income increase 11% total revenue increaseTripled net cash position Phase 3 program with fosmanogepix progressing as plannedFinancial guidance FY 2026: Double-digit increase in total revenue and operating profitConference call and webcast today at 4 p.m. (CET) Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 17, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharma company committed to meeting the needs of patients with severe</description>
</item>
<item>
<title>Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresemba-isavuconazole-sales-performance-061500767</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresemba-isavuconazole-sales-performance-061500767</guid>
<pubDate>Mon, 09 Feb 2026 06:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. David Veitch, Basilea’</description>
</item>
<item>
<title>Basilea joins INCATE to support antifungal innovation</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-joins-incate-support-antifungal-061500617</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-joins-incate-support-antifungal-061500617</guid>
<pubDate>Tue, 13 Jan 2026 06:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, January 13, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with INCATE (INCubator for Antibacterial Therapies in Europe), an antimicrobial incubator supporting the advancement of early stage anti-infectives. Basilea is joining INCATE as an industry partner, bringing extensive preclinical, clinical, and c</description>
</item>
<item>
<title>Basilea provides portfolio update and outlook</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-provides-portfolio-outlook-061500793</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-provides-portfolio-outlook-061500793</guid>
<pubDate>Thu, 08 Jan 2026 06:15:00 GMT</pubDate>
<description>Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactamFosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as plannedTwo new preclinical collaborations to develop novel antibacterial and antifungal drugsCresemba continued strong double-digit in-market sales growth Allschwil, Switzerland, January 08, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutica</description>
</item>
<item>
<title>Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-prokaryotics-enter-collaboration-develop-061500167</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-prokaryotics-enter-collaboration-develop-061500167</guid>
<pubDate>Wed, 07 Jan 2026 06:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced an agreement with Prokaryotics Inc., a privately held US-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatm</description>
</item>
<item>
<title>Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/prokaryotics-and-basilea-enter-collaboration-to-develop-a-novel-broad-spectrum-antifungal-for-severe-invasive-infections</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/prokaryotics-and-basilea-enter-collaboration-to-develop-a-novel-broad-spectrum-antifungal-for-severe-invasive-infections</guid>
<pubDate>Wed, 07 Jan 2026 06:15:00 GMT</pubDate>
<description>Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</description>
</item>
<item>
<title>Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-and-phare-bio-enter-partnership-combining-anti-infectives-industry-expertise-with-unique-ai-capabilities-for-the-development-of-a-novel-antibiotic</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-and-phare-bio-enter-partnership-combining-anti-infectives-industry-expertise-with-unique-ai-capabilities-for-the-development-of-a-novel-antibiotic</guid>
<pubDate>Thu, 11 Dec 2025 06:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a partnership with Phare Bio Inc., Boston (USA), a biotech social venture that uses Artificial Intelligence (AI) to accelerate antibiotic discovery and development. Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules wi</description>
</item>
<item>
<title>Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/phare-bio-and-basilea-announce-landmark-partnership-to-develop-next-generation-broad-spectrum-antibiotic-using-ai</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/phare-bio-and-basilea-announce-landmark-partnership-to-develop-next-generation-broad-spectrum-antibiotic-using-ai</guid>
<pubDate>Thu, 11 Dec 2025 06:15:00 GMT</pubDate>
<description>BOSTON, December 11, 2025--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-</description>
</item>
<item>
<title>Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresembar-isavuconazole-sales-performance-in-europe-triggers-usd-30-million-milestone-payment-to-basilea</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresembar-isavuconazole-sales-performance-in-europe-triggers-usd-30-million-milestone-payment-to-basilea</guid>
<pubDate>Tue, 04 Nov 2025 06:15:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in Europe exceeded the threshold triggering a USD 30 million sales milestone payment. David V</description>
</item>
<item>
<title>Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-awarded-barda-contract-for-the-development-of-novel-oral-phase-3-ready-antibiotic-ceftibuten-ledaborbactam</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-awarded-barda-contract-for-the-development-of-novel-oral-phase-3-ready-antibiotic-ceftibuten-ledaborbactam</guid>
<pubDate>Thu, 25 Sep 2025 05:15:00 GMT</pubDate>
<description>- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority</description>
</item>
<item>
<title>Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-usd-25-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-usd-25-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062</guid>
<pubDate>Tue, 16 Sep 2025 05:15:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed t</description>
</item>
<item>
<title>Basilea on track with strong 2025 half-year results</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-on-track-with-strong-2025-half-year-results</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-on-track-with-strong-2025-half-year-results</guid>
<pubDate>Tue, 19 Aug 2025 05:15:00 GMT</pubDate>
<description>Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commerci</description>
</item>
<item>
<title>Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic</guid>
<pubDate>Thu, 14 Aug 2025 05:15:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase</description>
</item>
<item>
<title>Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-initiates-phase-3-study-with-antifungal-fosmanogepix-in-invasive-mold-infections</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-initiates-phase-3-study-with-antifungal-fosmanogepix-in-invasive-mold-infections</guid>
<pubDate>Tue, 29 Jul 2025 05:15:00 GMT</pubDate>
<description>Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal</description>
</item>
<item>
<title>Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-usd-39-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-receives-usd-39-million-funding-under-barda-agreement-to-continue-to-advance-novel-antifungals-fosmanogepix-and-bal2062</guid>
<pubDate>Tue, 08 Jul 2025 05:15:00 GMT</pubDate>
<description>Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, committed the ne</description>
</item>
<item>
<title>Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-further-milestone-payment-to-basilea</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/strong-cresembar-isavuconazole-sales-performance-in-asia-pacific-and-china-triggers-further-milestone-payment-to-basilea</guid>
<pubDate>Thu, 05 Jun 2025 05:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering the second USD 2.5 million milestone payment this year. David V</description>
</item>
<item>
<title>Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States</title>
<link>https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-commercial-availability-of-antibiotic-zevterar-ceftobiprole-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/basilea-pharmaceutica-ag/news/basilea-announces-commercial-availability-of-antibiotic-zevterar-ceftobiprole-in-the-united-states</guid>
<pubDate>Tue, 20 May 2025 05:15:00 GMT</pubDate>
<description>Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea’s partner Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). Zevtera is used in h</description>
</item>
</channel>
</rss>